Observation versus antiplatelet therapy as primary prophylaxis for thrombosis in low-risk essential thrombocythemia

Blood

Volumn 116, Issue 8, 2010, Pages 1205-1210

  Alvarez Larrán, Alberto ^a   Cervantes, Francisco ^b   Pereira, Arturo ^b   Arellano Rodrigo, Eduardo ^b,c   Pérez Andreu, Virginia ^d   Hernández Boluda, Juan Carlos ^e   Ayats, Ramón ^f   Salvador, Carlos ^g   Muntañola, Ana ^h   Bellosillo, Beatriz ^a   Vicente, Vicente ^d   Hernández Nieto, Luis ⁱ   Burgaleta, Carmen ^j   Xicoy, Blanca ^k   Besses, Carlos ^a  

^a HOSPITAL DEL MAR   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d HOSPITAL MORALES MESEGUER   (Spain)

^e HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL UNIVERSITARIO MIGUEL SERVET   (Spain)

^h HOSPITAL MÚTUA DE TERRASSA   (Spain)

ⁱ HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^j UNIVERSITY OF ALCALÁ   (Spain)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPYRIDAMOLE; TICLOPIDINE; TRIFLUSAL;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CHILD; CIGARETTE SMOKING; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENE MUTATION; HEMATOLOGICAL PARAMETERS; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INTERMETHOD COMPARISON; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; OBSERVATION; PRIORITY JOURNAL; PROBABILITY; RETROSPECTIVE STUDY; RISK; RISK FACTOR; SURVIVAL RATE; THROMBOCYTE COUNT; THROMBOCYTHEMIA; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME; VEIN THROMBOSIS; WATCHFUL WAITING;

EID: 77956524019     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-263319     Document Type: Article

References (28)

1. Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128(3):275-290. (Pubitemid 40216149)
2. Besses C, Cervantes F, Pereira A, et al. Major vascular complications in essential thrombocythemia: a study of the predictive factors in a series of 148 patients. Leukemia. 1999;13(2):150-154. (Pubitemid 29092645)
3. Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8(3):556-562. (Pubitemid 20087557)
4. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia. 2008;22(5):905-914. (Pubitemid 351698623)
5. Birgegard G. Long-term management of thrombocytosis in essential thrombocythaemia. Ann Hematol. 2009;88(1):1-10.
6. Tefferi A, Barbui T. bcr/abl-negative, classic myeloproliferative disorders: diagnosis and treatment. Mayo Clin Proc. 2005;80(9):1220-1232. (Pubitemid 41233360)
7. Barbui T, Finazzi G. When and how to treat essential thrombocythemia. N Engl J Med. 2005;353(1):85-86. (Pubitemid 41007812)
8. Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. (Pubitemid 40386783)
9. Levine RL, Wadleigh M, Cools J, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. (Pubitemid 40544655)
10. Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. (Pubitemid 40570926)
11. Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366(9501):1945-1953. (Pubitemid 41713984)
12. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-124. (Pubitemid 38056222)
13. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353(1):33-45. (Pubitemid 41007805)
14. Griesshammer M. Risk factors for thrombosis and bleeding and their influence on therapeutic decisions in patients with essential thrombocythemia. Semin Thromb Hemost. 2006;32(4Pt2):372-380.
15. Lussana F, Caberlon S, Pagani C, et al. Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review. Thromb Res. 2009;124(4):409-417.
16. Carobbio A, Antonioli E, Guglielmelli P, et al. Leukocytosis and risk stratification assessment in essential thrombocythemia. J Clin Oncol. 2008;26(16):2732-2736.
17. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood. 2007;110(4):1092-1097. (Pubitemid 47281402)
18. Grunkemeier GL, Jin R, Eijkemans MJ, Takkenberg JJ. Actual and actuarial probabilities of competing risks: apples and lemons. Ann Thorac Surg. 2007;83(5):1586-1592. (Pubitemid 46616757)
19. Jann B. Splitting time-span records with categorical time-varying covariates. Stata J. 2004;4(2):221-222.
20. Coviello VBN. Cumulative incidence estimation in the presence of competing risks. Stata J. 2004;4(2):103-112.
21. Beer PA, Green AR. Pathogenesis and management of essential thrombocythemia. Hematology Am Soc Hematol Educ Program. 2009:621-628.
22. van Genderen PJ, Mulder PG, Waleboer M, van de Moesdijk D, Michiels JJ. Prevention and treatment of thrombotic complications in essential thrombocythaemia: efficacy and safety of aspirin. Br J Haematol. 1997;97(1):179-184. (Pubitemid 27179585)
23. Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy - a follow-up study in 68 patients. Clin Appl Thromb Hemost. 2000;6(1):31-35. (Pubitemid 30022952)
24. Alvarez-Larran A, Cervantes F, Bellosillo B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21(6):1218-1223. (Pubitemid 46831811)
25. Tefferi A, Fonseca R, Pereira DL, Hoagland HC. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001;76(1):22-28. (Pubitemid 32042994)
26. Jantunen R, Juvonen E, Ikkala E, et al. The predictive value of vascular risk factors and gender for the development of thrombotic complications in essential thrombocythemia. Ann Hematol. 2001;80(2):74-78. (Pubitemid 32177952)
27. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000;355(9212):1295- 1302.
28. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136(2):161-172. (Pubitemid 34073943)